Kura Oncology
KURA
148 hedge funds and large institutions have $978M invested in Kura Oncology in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 41 reducing their positions, and 19 closing their positions.
131% more call options, than puts
Call options by funds: $3.41M | Put options by funds: $1.48M
39% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 41
3.97% more ownership
Funds ownership: 103.03% → 107% (+4%)
0% more funds holding
Funds holding: 148 → 148 (0)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
22% less capital invested
Capital invested by funds: $1.26B → $978M (-$281M)
64% less funds holding in top 10
Funds holding in top 10: 11 → 4 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$20.6M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$9.12M |
| 3 |
Goldman Sachs
New York
|
+$7.26M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.06M |
| 5 |
Millennium Management
New York
|
+$6.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$32.8M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$19.7M |
| 3 |
CC
Commodore Capital
New York
|
-$14.3M |
| 4 |
TP
Thunderbird Partners
London,
United Kingdom
|
-$9.4M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$7.9M |
KURA Hedge Fund Activity: Q3 2022 in Review
148 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q3 2022, worth a combined $978M — down 22% from $1.26B a quarter earlier.
Fund positioning in KURA was balanced in Q3 2022: 19 funds opened new positions, 19 closed out, 57 added to existing stakes and 41 trimmed.
The largest buyer was State Street, adding an estimated $20.6M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $32.8M sold.
- 148 institutional investors held Kura Oncology (KURA) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $978M of Kura Oncology stock for Q3 2022, down 22% quarter-over-quarter.
- 19 funds opened new Kura Oncology positions in Q3 2022 and 19 closed out, a net change of 0 holders.
- The largest Kura Oncology buyer in Q3 2022 was State Street, an estimated $20.6M added.
- The largest Kura Oncology seller in Q3 2022 was Eventide Asset Management, an estimated $32.8M sold.
Based on aggregated 13F filings for Q3 2022.